Core Viewpoint - The approval of the non-covalent BTK inhibitor, Pirtobrutinib (捷帕力®), for a new indication in China represents a significant advancement for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have previously undergone treatment with BTK inhibitors [1][2] Group 1: Approval and Indication - Pirtobrutinib has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including a BTK inhibitor [1] - The drug was previously approved by the FDA in January 2023 and is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two systemic therapies, including BTK inhibitors, by October 2024 in China [1] Group 2: Clinical Study Results - The approval is based on the results of the international, multicenter, randomized controlled BRUIN-CLL-321 Phase III study, which included 238 patients previously treated with covalent BTK inhibitors [2] - Pirtobrutinib significantly extended the median progression-free survival (PFS) to 14.0 months compared to 8.7 months for the control group (HR=0.54) and had a lower treatment-related discontinuation rate of 5.2% versus 21.1% [2] Group 3: Market Impact and Strategy - The approval of Pirtobrutinib for CLL/SLL in China is a major breakthrough, allowing local patients to benefit from this global innovation [2] - The company aims to leverage its leading brand and expertise in the oncology field to accelerate the accessibility of this innovative therapy for more patients in need [2]

Core Viewpoint - Junshi Biosciences (01877) reported a total revenue of approximately 2.498 billion yuan for 2025, representing a year-on-year growth of 28.23% [1] - The net loss attributable to the parent company's owners was approximately 874 million yuan, a reduction of 31.74% compared to the previous year [1] - The basic loss per share was 0.87 yuan [1] Revenue Growth - The increase in revenue was primarily driven by significant sales growth of the core product, Toripalimab injection (brand name: Tuoyi®), in the domestic market [1] Loss Reduction - The reduction in losses was attributed to the implementation of a stock option incentive plan in 2025, which increased share-based payment expenses [1] - The company actively executed the "quality improvement and efficiency enhancement" action plan, continuously strengthening cost control measures [1] - Focused and efficient investment in the R&D pipeline, along with reduced unit production costs and improved sales efficiency, contributed to the decrease in loss amounts compared to the same period last year [1]

Core Viewpoint - Junshi Biosciences (01877) reported a total revenue of approximately 2.498 billion yuan for 2025, representing a year-on-year increase of 28.23% [1] - The net loss attributable to the parent company was approximately 874 million yuan, narrowing by 31.74% year-on-year, with a basic loss per share of 0.87 yuan [1] Revenue Growth - The increase in revenue was primarily driven by significant sales growth of the core product, Toripalimab injection (brand name: Tuoyi), in the domestic market [1] Loss Reduction - The reduction in losses was mainly due to the implementation of a stock option incentive plan in 2025, which increased share-based payment expenses [1] - The company actively executed the "quality improvement and efficiency enhancement" action plan, continuously strengthening cost control measures, focusing on the R&D pipeline, efficiently investing, reducing unit production costs, and improving sales efficiency, leading to a decrease in loss amounts compared to the same period last year [1]

Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profitability for the fiscal year 2025, indicating strong business performance driven by product sales and licensing agreements [1] Financial Performance - The company achieved total revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share were RMB 1.29 [1] Revenue Drivers - The increase in revenue was primarily due to higher sales volumes of injectable Tisotumab Vedotin and injectable Vedolizumab, contributing to increased sales revenue [1] - Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tisotumab Vedotin outside Greater China, leading to a substantial increase in licensing revenue [1]

Core Insights - Rongchang Biopharma (09995.HK) reported a significant increase in revenue and net profit for the fiscal year 2025, with total revenue reaching RMB 3.25 billion, a year-on-year increase of 89.36% [1] - The company achieved a net profit attributable to shareholders of RMB 700 million, and a net profit of RMB 650.56 million after deducting non-recurring gains and losses [1] - Total assets at the end of the reporting period amounted to RMB 7.24 billion, reflecting a growth of 31.65% compared to the beginning of the period [1] Financial Performance - The equity attributable to shareholders increased by 81.40% to RMB 3.60 billion [1] - Core products, including Taitasip and Vidisicimab, saw rapid growth in domestic sales, becoming the main drivers of the company's performance [1] - The company successfully established a significant partnership with VorBiopharma Inc., granting exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [1] Operational Efficiency - The company implemented management optimizations and production process iterations, resulting in reduced unit production costs and improved gross profit margins [1] - A notable decrease in sales expense ratio contributed to the overall improvement in profitability efficiency [1] - The company anticipates a turnaround in net profit for the fiscal year 2025, projecting a return to profitability [1]

Core Insights - The 2026 Tech Trends Report highlights that technology will reshape various aspects of life, creating both opportunities and challenges [1][2] Group 1: Technological Advancements - AI is rapidly transforming industries, with OpenAI's ChatGPT reaching 800 million weekly active users, an eightfold increase since late 2023 [3] - 10% of U.S. companies are now utilizing AI in their products or services, particularly in tech, manufacturing, and finance sectors [3] - The global SaaS market has seen AI services capture 6% of its share, equating to $18 billion [3] - Major tech companies are investing heavily in data centers, with spending expected to reach $1.3 trillion by 2027 [3] Group 2: AI and Human Interaction - There is a growing disconnect between technological advancements and human emotional needs, leading to increased loneliness and distrust [2] - 33% of teenagers have used AI for social interaction, and 25% of adults aged 18-39 believe AI could replace real-life relationships [3] - The rise of AI companions is accelerating faster than social media and online gaming, with a 132% increase in searches for "falling in love with AI" [3] Group 3: Market Dynamics - The demand for AI is leading to a significant increase in power consumption, with projections indicating that by 2030, over 10% of U.S. electricity will be used for AI [3] - The efficiency of data centers is under scrutiny, as seen in Virginia, where water usage has surged by 63% due to data center operations [3] - The report indicates a shift in consumer behavior, with advertising dollars moving from traditional media to social media platforms, reflecting changing engagement patterns [3] Group 4: Industry Comparisons - In the shipping industry, Chinese ports have automated 88% of container operations, while U.S. shipyards account for only 0.04% of global production [3] - The report discusses the potential for lunar bases to host data centers, leveraging low temperatures for cooling and accessing resources like water and helium-3 [3]

（股份代號：9995） 內幕消息 2025年度業績快報公告 本公告由榮昌生物製藥（煙台）股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則（「上市規則」）第13.09(2)(a)條及第13.10B條項下披露責任以及 證券及期貨條例（香港法例第571章）第XIVA部項下的內幕消息條文（如上市規則 所定義）作出。 本公告所載本公司2025年度主要財務數據，乃根據《中國企業會計準則》編製，為 初步核算數據，未經會計師事務所審計，具體數據以本公司2025年年度報告披露 的數據為準，提請投資者注意投資風險。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） | | | | 增減變動 | | --- | --- | --- | --- | | 項目 | 本報告期 | 上年同期 | 幅度(%) | | 營業總收入 | ...

Core Viewpoint - The announcement indicates a reduction in the shareholding percentage of major shareholders in Sanofi Guojian due to a share reduction plan executed by Dajia International, which does not trigger a mandatory takeover bid and does not change the control of the company [1] Group 1 - Dajia International and its concerted parties reduced their holdings by 5.8948 million shares, representing 0.95% of the company's total share capital [1] - Following the reduction and an increase in total share capital due to stock incentives, the combined shareholding percentage decreased from 84.96% to 83.83% [1] - The share reduction plan has been completed, and the controlling shareholder and actual controller of the company remain unchanged [1]

Core Viewpoint - The resignation of Ren Hui, the president of Boya Bio, after less than 10 months in office, coincides with the company's forecast of a significant decline in net profit for 2025, primarily due to asset impairment from an acquisition [1][5]. Group 1: Company Leadership Changes - Ren Hui resigned from his positions as president and board member of Boya Bio due to work changes, and his resignation leaves the president position temporarily vacant [1][2]. - Ren Hui was appointed as president on May 16, 2025, and previously served as vice president starting October 23, 2024, with a reported pre-tax salary of 93,000 yuan in 2024 [2][3]. Group 2: Financial Performance - Boya Bio's 2025 annual performance forecast indicates a net profit decline of 65.62% to 73.55%, estimated between 105 million yuan and 136.5 million yuan, with a projected non-recurring net loss of 7.5 million to 15 million yuan [5][6]. - The decline in financial performance is attributed to three main factors: impairment losses from the acquisition of Green Cross Hong Kong Holdings, depreciation and amortization impacts from the acquisition, and decreased gross margins in the blood products business due to intensified market competition and regulatory changes [6][7]. Group 3: Acquisition Impact - The acquisition of Green Cross Hong Kong Holdings in November 2024 has led to significant impairment losses, totaling approximately 300 million yuan, affecting the company's financial outlook for 2025 [6][7]. - The performance of the acquired company's products, particularly hyaluronic acid, has been negatively impacted by a downturn in the market, contributing to the overall financial challenges faced by Boya Bio [6][7]. Group 4: Shareholder Actions - Despite the poor financial outlook, the controlling shareholder, China Resources Pharmaceutical Group, has increased its stake in Boya Bio, acquiring an additional 6.0509 million shares, representing 1.20% of the total share capital [4][6]. - The stock price of Boya Bio has been on a downward trend since October 2024, with a significant drop from a peak of 41.51 yuan to a closing price of 22.25 yuan as of February 27, 2026, resulting in a market capitalization of approximately 11.22 billion yuan [6][7].

Core Viewpoint - Olin Bio (688319.SH) reported a revenue of 704 million yuan for the fiscal year 2025, marking a year-on-year growth of 19.58% [1] Financial Performance - The net profit attributable to the parent company's shareholders reached 22.23 million yuan, reflecting a year-on-year increase of 7.10% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 9.88 million yuan, showing a year-on-year decrease of 11.64% [1] Market Activity - The company has been actively enhancing market promotion, leading to steady growth in the sales of tetanus vaccine [1]